Literature DB >> 33275332

Update on Guidelines for the Management of Cancer-Associated Thrombosis.

Michael B Streiff1, Syed Ali Abutalib2, Dominique Farge3,4, Martina Murphy5, Jean M Connors6,7,8, Gregory Piazza6,7,5.   

Abstract

Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT. IMPLICATIONS FOR PRACTICE: Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice.
© 2020 AlphaMed Press.

Entities:  

Keywords:  Cancer-associated thrombosis; Guideline; Management; Prevention; Treatment

Year:  2020        PMID: 33275332      PMCID: PMC7794170          DOI: 10.1002/onco.13596

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  51 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

3.  Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH.

Authors:  M Di Nisio; M Carrier; G H Lyman; A A Khorana
Journal:  J Thromb Haemost       Date:  2014-09-22       Impact factor: 5.824

4.  Risk of Arterial Thromboembolism in Patients With Cancer.

Authors:  Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Peter M Okin; Mitchell S V Elkind; Katherine S Panageas; Lisa M DeAngelis
Journal:  J Am Coll Cardiol       Date:  2017-08-22       Impact factor: 24.094

Review 5.  Thrombosis in the setting of cancer.

Authors:  Michael B Streiff
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.

Authors:  David E Gerber; Jodi B Segal; M Yair Levy; Joyce Kane; Richard J Jones; Michael B Streiff
Journal:  Blood       Date:  2008-05-14       Impact factor: 22.113

7.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

8.  Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Nigel S Key; Alok A Khorana; Nicole M Kuderer; Kari Bohlke; Agnes Y Y Lee; Juan I Arcelus; Sandra L Wong; Edward P Balaban; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Mark N Levine; Howard A Liebman; Margaret A Tempero; Gary H Lyman; Anna Falanga
Journal:  J Clin Oncol       Date:  2019-08-05       Impact factor: 44.544

Review 9.  Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants.

Authors:  Vincent Geldhof; Christophe Vandenbriele; Peter Verhamme; Thomas Vanassche
Journal:  Thromb J       Date:  2014-10-13

10.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Authors:  Giancarlo Agnelli; Cecilia Becattini; Guy Meyer; Andres Muñoz; Menno V Huisman; Jean M Connors; Alexander Cohen; Rupert Bauersachs; Benjamin Brenner; Adam Torbicki; Maria R Sueiro; Catherine Lambert; Gualberto Gussoni; Mauro Campanini; Andrea Fontanella; Giorgio Vescovo; Melina Verso
Journal:  N Engl J Med       Date:  2020-03-29       Impact factor: 91.245

View more
  23 in total

1.  'Spot the CLOT': What cancer patients want to know.

Authors:  Julia A Bayadinova; Laurie A Sardo; Vanessa Higgins-Nogareda; Jill Scott; Brooke MacKinnon
Journal:  Can Oncol Nurs J       Date:  2022-02-01

2. 

Authors:  Julia A Bayadinova; Laurie A Sardo; Vanessa Higgins-Nogareda; Jill Scott; Brooke MacKinnon
Journal:  Can Oncol Nurs J       Date:  2022-02-01

3.  Anticoagulation and bleeding in the cancer patient.

Authors:  Andres Escobar; Ahmed M Salem; Kodwo Dickson; Tami N Johnson; Kathyrn J Burk; Lara Bashoura; Saadia A Faiz
Journal:  Support Care Cancer       Date:  2022-05-17       Impact factor: 3.359

4.  Evidence-Based Nursing Model in Interventional Thrombolysis for Acute Lower Extremity Arterial Embolism.

Authors:  Meijuan Yang; Lijiao Chen; Min Zhang; Xiaoling Huang; Wenjun Zhao; Hui Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-05-25       Impact factor: 3.009

Review 5.  Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Authors:  Lara A Kahale; Charbel F Matar; Maram B Hakoum; Ibrahim G Tsolakian; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-12-08

Review 6.  Survival of patients with cancer associated thrombosis at the Uganda Cancer Institute.

Authors:  Clement D Okello; Yusuf Mulumba; Abrahams Omoding; Henry Ddungu; Jackson Orem
Journal:  Ecancermedicalscience       Date:  2021-03-25

Review 7.  Cancer-Associated Thrombosis: A New Light on an Old Story.

Authors:  Sidrah Shah; Afroditi Karathanasi; Antonios Revythis; Evangelia Ioannidou; Stergios Boussios
Journal:  Diseases       Date:  2021-05-04

Review 8.  Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Authors:  Robert Benamouzig; Maxime Guenoun; David Deutsch; Laurent Fauchier
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-18       Impact factor: 3.947

9.  Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.

Authors:  Thure Filskov Overvad; Anne Gulbech Ording; Peter Brønnum Nielsen; Flemming Skjøth; Ida Ehlers Albertsen; Simon Noble; Anders Krog Vistisen; Inger Lise Gade; Marianne Tang Severinsen; Gregory Piazza; Torben Bjerregaard Larsen
Journal:  Blood Adv       Date:  2022-05-24

Review 10.  Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship.

Authors:  Claudia de Wall; Johann Bauersachs; Dominik Berliner
Journal:  Clin Exp Metastasis       Date:  2021-06-12       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.